BioAge Labs (NASDAQ:BIOA) Stock Price Down 8.7% – Should You Sell?

BioAge Labs, Inc. (NASDAQ:BIOA)’s stock price dropped 8.7% during trading on Monday . The stock traded as low as $16.26 and last traded at $16.12. Approximately 107,037 shares traded hands during trading, a decline of 83% from the average daily volume of 621,039 shares. The stock had previously closed at $17.66.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Oppenheimer initiated coverage on shares of BioAge Labs in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 target price for the company. Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday. Needham & Company LLC assumed coverage on shares of BioAge Labs in a report on Friday, March 27th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, BTIG Research initiated coverage on BioAge Labs in a research note on Wednesday, May 13th. They set a “buy” rating and a $40.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, BioAge Labs currently has an average rating of “Moderate Buy” and an average target price of $45.00.

BioAge Labs Trading Up 0.7%

The stock has a market capitalization of $732.59 million, a P/E ratio of -6.86 and a beta of 0.99. The stock’s 50 day simple moving average is $17.97 and its 200 day simple moving average is $15.99.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.19. The company had revenue of $2.77 million during the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. On average, sell-side analysts expect that BioAge Labs, Inc. will post -2.59 EPS for the current fiscal year.

Institutional Investors Weigh In On BioAge Labs

A number of institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new position in BioAge Labs in the third quarter worth $181,000. R Squared Ltd bought a new position in shares of BioAge Labs in the 3rd quarter worth about $154,000. Russell Investments Group Ltd. lifted its position in shares of BioAge Labs by 812.1% in the 4th quarter. Russell Investments Group Ltd. now owns 41,308 shares of the company’s stock worth $547,000 after buying an additional 36,779 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of BioAge Labs in the 4th quarter valued at about $520,000. Finally, Barclays PLC grew its position in shares of BioAge Labs by 9.3% during the 4th quarter. Barclays PLC now owns 37,780 shares of the company’s stock valued at $500,000 after buying an additional 3,222 shares during the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.